JP2014530231A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530231A5
JP2014530231A5 JP2014535166A JP2014535166A JP2014530231A5 JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5 JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014535166 A JP2014535166 A JP 2014535166A JP 2014530231 A5 JP2014530231 A5 JP 2014530231A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
container
mdi
metered dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530231A (ja
JP5818290B2 (ja
Filing date
Publication date
Priority claimed from GB201117621A external-priority patent/GB201117621D0/en
Application filed filed Critical
Publication of JP2014530231A publication Critical patent/JP2014530231A/ja
Publication of JP2014530231A5 publication Critical patent/JP2014530231A5/ja
Application granted granted Critical
Publication of JP5818290B2 publication Critical patent/JP5818290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535166A 2011-10-12 2012-10-12 硫酸サルブタモールを含有する組成物 Active JP5818290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201117621A GB201117621D0 (en) 2011-10-12 2011-10-12 Compositions
GB1117621.1 2011-10-12
PCT/GB2012/052542 WO2013054135A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (3)

Publication Number Publication Date
JP2014530231A JP2014530231A (ja) 2014-11-17
JP2014530231A5 true JP2014530231A5 (OSRAM) 2014-12-25
JP5818290B2 JP5818290B2 (ja) 2015-11-18

Family

ID=45091933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535166A Active JP5818290B2 (ja) 2011-10-12 2012-10-12 硫酸サルブタモールを含有する組成物

Country Status (12)

Country Link
US (1) US9114164B2 (OSRAM)
EP (1) EP2766005B1 (OSRAM)
JP (1) JP5818290B2 (OSRAM)
CN (1) CN103857388B (OSRAM)
AU (1) AU2012322453B2 (OSRAM)
BR (1) BR112014008609B1 (OSRAM)
CA (1) CA2851764C (OSRAM)
ES (1) ES2556585T3 (OSRAM)
GB (1) GB201117621D0 (OSRAM)
MX (1) MX336225B (OSRAM)
WO (1) WO2013054135A1 (OSRAM)
ZA (1) ZA201402234B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3236967B1 (en) 2014-12-22 2019-10-16 SUDA Pharmaceuticals Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN108289843B (zh) * 2015-12-04 2021-08-17 墨西哥氟石股份公司 药物组合物
US10792256B2 (en) * 2016-09-19 2020-10-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6781831B2 (ja) * 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
WO2018051128A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
FR3130554B1 (fr) 2021-12-20 2024-10-18 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
ES2216800T3 (es) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
SK81197A3 (en) 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
JPH11503352A (ja) 1995-04-14 1999-03-26 グラクソ、ウェルカム、インコーポレーテッド プロピオン酸フルチカゾン用計量投与用吸入器
WO1999016421A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338680C (en) 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
GB2392164B (en) 1999-09-11 2004-04-07 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Similar Documents

Publication Publication Date Title
JP2014530231A5 (OSRAM)
JP2014528470A5 (OSRAM)
JP2007106777A5 (OSRAM)
Stein et al. The history of therapeutic aerosols: a chronological review
Zhou et al. Emerging inhalation aerosol devices and strategies: where are we headed?
JP2010132695A5 (OSRAM)
HRP20140582T4 (hr) Kombinacijska terapija za copd
JP2009269923A5 (OSRAM)
MX2014004279A (es) Composiciones que comprenden sulfato de salbutamol.
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
GB201118188D0 (en) Manufacture of medicinal aerosol canisters
JP2013544781A5 (OSRAM)
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
NZ701261A (en) Novel dosage form and formulation of abediterol
PH12014502746A1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
HRP20140550T1 (hr) Aerosolna formulacija za copd
CN111936124A (zh) 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
WO2012040228A3 (en) Aerosol composition for administering drugs
MX370890B (es) Composición que comprende sulfato de salbutamol.
WO2011061498A3 (en) Inhalation solutions
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
MX2014001940A (es) Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal.